MapLight Therapeutics — Valuation, Funding & Investors

Recent changes

Sep 9, 2026Sep 9, 2026Raised $150M Follow-on offering SEC EDGAR

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Sep 9, 2026	Follow-on offering	$150M	—		SEC EDGAR

Latest Pulse

Sep 11, 2026Newly Public Biotechs Are Already Back For More CashMapLight Therapeutics filed a $150 million follow-on just eleven months after its own IPO, part of a broader 2026 pattern of newly public biotechs returning to capital markets well ahead of their first pivotal data readouts.→

Coverage Timeline

newest first

Sep 11, 2026IPONewly Public Biotechs Are Already Back For More Cash→

All Coverage

IPO· Sep 10, 2026

Newly Public Biotechs Are Already Back For More Cash

IPO

Newly Public Biotechs Are Already Back For More Cash

MapLight Therapeutics filed a $150 million follow-on just eleven months after its own IPO, part of a broader 2026 pattern of newly public biotechs returning to capital markets well ahead of their first pivotal data readouts.

Sep 10, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGARprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction